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The diagnosis of viral infections is important for the accurate management of patients with
infectious diseases and for the monitoring of the course of epidemics in susceptible populations.
The utility of traditional viral diagnostic assays is limited by the time, expense, and expertise
required for theperformance oftissueculture techniques. Similarly, theapplication ofimmunoas-
say techniques has been inhibited bythe limited degrees ofsensitivity and specificity which can be
attained by most immunoassay methods.
Recently, techniques for the identification of DNA and RNA have been applied to the
detection of viral nucleic acids in clinical samples. Such assays have a number of potential
advantages over corresponding immunoassays directed at the detection ofviral antigens. In order
to be generally applicable to clinical diagnosis, however, formats for the detection ofviral nucleic
acids have to be devised which allow for the reproducible quantitation oftarget DNA or RNA in
human body fluids. Furthermore, formats need to be devised which allow enhanced assay
sensitivity while maintaining high degrees of specificity and reproducibility. The use of
non-isotopic labeling, liquid-phase hybridization, and target amplification techniques offers
partial solutions to these problems. The development ofpractical assays for the detection ofviral
nucleic acids under a broad range of clinical and laboratory conditions would represent a major
advance in the ability ofphysicians to care for patients with suspected infections.
Since 1980, we have witnessed an epidemic ofa devastating new viral disease and a
corresponding search for new methods for disease treatment and prevention. During
the course oftheacquired immunodeficiency syndrome (AIDS) epidemic, the expand-
ing knowledge of the basic science of retroviruses has been applied rapidly to the
development ofdiagnostic tests for the identification ofinfected individuals and for the
monitoring of disease transmission. The knowledge gained from the application of
these diagnostic tests has been invaluable in the understanding ofthe epidemic and in
the development ofstrategies for disease prevention and treatment [1-6].
The most important recent development in the area of viral diagnosis has been the
application of nucleic acid hybridization techniques to the direct detection of viral
nucleic acid in human body fluids. Such assays utilize labeled deoxyribonucleic acid
(DNA) or ribonucleic acid (RNA) complementary to viral genomes extracted from
virions in clinical samples. It should be noted that this technique is a direct extension of
a great deal of research effort which has been applied to the understanding of the
biochemistry and biophysics of nucleic acid interactions in aqueous solutions and on
solid-phase surfaces. Furthermore, the vast body of information relating to the
nucleotide sequences ofpathogenic viruses can be directly applied to the construction
ofnucleotide probes and to their use for viral detection and characterization.
131
Abbreviations: AIDS: acquired immunodeficiency syndrome CMV: cytomegalovirus DNA: deoxyri-
bonucleic acid HIV: human immunodeficiency virus RNA: ribonucleic acid
This work was supported by Grant ROI DK 40540, and Contracts NO1-HB 67017 and NO1-AI-52579
from the National Institutes ofHealth.
Copyright e 1989 by The Yale Journal of Biology and Medicine, Inc.
All rights ofreproduction in any form reserved.YOLKEN ET AL.
Nucleic acid hybridization offers a number of advantages in terms of the accurate
diagnosis and study ofviral diseases [7-10]. First, the specificity ofnucleotide base-pair
interactions allows definitive identification ofviral sequences in human body fluids. This
specificity should permit the direct identification ofgenetic markers ofviral pathogene-
sis. Such identification should result not only in the accurate diagnosis ofviral infections
but also in the accurate prediction ofthe disease process and in the efficient targeting of
antiviral chemotherapy.
Another important advantage of nucleic acid hybridization techniques is that they
are capable of detecting viral DNA sequences which are not expressing RNA and
which are not being translated into measurable proteins. This property allows the
detection ofvirus in a latent state beforethecompleteclinical expressionofthedisease,
which has proven to be valuable for the study ofcomplicated disease processes such as
those associated with human herpesviruses [11] and human immunodeficiency virus
infections [12].
Another advantage of nucleic acid hybridization techniques is that they allow the
detection ofnew viral pathogens before the antigenic nature ofthe viruses is elucidated.
Since the sequencing of viral genomes can be accomplished fairly rapidly, this process
permits the implementation of diagnostic assays soon after a viral species has been
identified as a possible human pathogen. Finally, the fact that nucleic acids can be easily
separated from proteins allows the detection ofviruses which are bound to endogenous
antibodies in the form of immune complexes or which are otherwise inaccessible to
labeled antibodies [13]. It is thus particularly effective to utilize nucleic acid hybridiza-
tiop techniques late in the course of illness when the ability to detect infection by
conventional techniques hasdiminished due tothegeneration ofa hostimmune response
to viral antigens [14]. Assays for the direct detection of viral nucleic acids have been
developed for a number of medically important viruses, including herpes simplex virus
[15], cytomegalovirus (CMV) [16], Epstein-Barr virus [17], varicella-zostervirus [18],
rotaviruses [19], adenoviruses [20], papilloma viruses [21], rabies [22], and human
immunodeficiency viruses.
Despite these advantages, there are still some limitations to the widespread
application of nucleic acid hybridization techniques to the clinical diagnosis of viral
infections. One limitation is related to the fact that hybridization techniques are often
not sufficiently sensitive for the detection of all viral nucleic acids in human body
fluids. The level of sensitivity is a particular problem when non-isotopic probes are
utilized [23-27]. Since it is difficult for clinical laboratories to utilize probes such as
32P at high levels of specific activity, this limitation is particularly problematic for
diagnostic testing. Another limitation of standard nucleic acid hybridization technol-
ogy for practical viral diagnosis is related to the solid-phase Southern transfer or
"dot-blot" detection formats which are widely used in research laboratories. While
such formats can be quite effective for the detection ofrelatively pure preparations of
nucleic acids, they are difficult to apply in situations in which the nucleic acids are not
fully exposed but are contaminated with viral and host proteins. Such proteins can
compete with the nucleic acids for binding sites on the solid phase and thus reduce the
diagnostic efficiency ofthe hybridization systems for the diagnosis ofviral infections.
There are a number of methods which can be utilized to improve the diagnostic
utility of nucleic acid hybridization procedures for the detection ofviral nucleic acids
in crude clinical samples. Onewayofimproving the kinetics and practicality ofnucleic
acid hybridization reactions is by the performance of hybridization reactions in a
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fluid-phase environment. Since the kinetics of nucleic acid reassociation are more
favorable in fluid phases as compared to the kinetics of reassociation on a solid-phase
surface, hybridization reactions can be performed more rapidly in such systems. Also,
such systems are not as limited by the presence of extraneous materials which can
compete for binding sites on the solid-phase surface [29]. Formats which make use of
fluid-phase reactions are thus more easily adaptable to the detection of viral nucleic
acids in crude clinical samples.
One system which utilizes mixed solid-phase and liquid-phase reactions makes use
of non-overlapping oligonucleotides in a "sandwich" hybridization format. In this
system, one oligonucleotide which is complementary to a target sequence is bound to
the solid phase, such as the well of a microtiter plate. A second oligonucleotide, which
is complementary to ajuxtaposed but non-overlapping sequence on the viral genome, is
labeled with a detectable marker and reacted with nucleic acids extracted from the
clinical specimen [9,20]. Ifthe specimen contains the virus to be measured, the labeled
marker is bound to the complementary viral nucleotides which are, in turn, bound to
the sequences immobilized on the solid-phase surface. Following the removal of
extraneous material by washing, the reaction is quantitated by the measurement ofthe
appropriate label. This format has been utilized to detect a number ofviral antigens in
body fluids. While the system originally utilized radioactive labels, it can also be
adapted to make use ofenzymatic and high-energy fluorescent markers [30].
Another approach to the performance of liquid-phase hybridization involves the
re-annealing of labeled probe and target sequences in liquid phase and the subsequent
binding of the nucleic acid hybrids to a solid-phase surface. This binding can be
accomplished by means of affinity columns or microtiter plates. In the latter case, one
method ofbinding nucleic acid duplexes to a solid phase makes use ofantibodies directed
at DNA-RNA hybrids [31,32]. The format for such systems is presented in Fig. 1. In
this system, biotin-labeled DNA is utilized for the detection of viral RNA and
biotin-labeled RNA is utilized for the detection ofviral DNA. Following completion of
the hybridization reaction in liquid phase, the probe is bound to the solid phase by means
of reaction to avidin or anti-biotin antibodies. The presence of DNA-RNA hybrids is
quantitated by reaction with enzyme-labeled anti-DNA-RNA antibody and enzyme
substrate using this assay system.
As little as 10 pg/ml of target RNA can be detected, using monoclonal hybridiza-
tion formats. This level ofsensitivity can be obtained following 20 minutes ofsubstrate
incubation, provided that substrates generating fluorescent products are utilized to
quantitate the enzymatic reaction (Fig. 2). When the colorigenic substrate nitro-
phenyl phosphate is utilized, a reaction period of more than two hours is required to
attain this degree of sensitivity (Fig. 3). Thus convenient colorimetric reactions with
alkaline phosphatase-labeled antibody can be used for this reaction system, provided
that longer incubation periods are utilized. The sensitivity of these assays compares
favorably with those which utilize radiolabeled probes for the detection ofviral RNA
[9,22].
Non-isotopic hybridization reactions allow the practical measurement of nucleic
acids, provided that the target nucleic acids are present in sufficient quantities. The
levels of sensitivity achieved are, however, somewhat less than those required for the
diagnosis ofall viral agents in human disease states.
A number of techniques have, however, recently been developed which can greatly
amplify the quantity of nucleic acid in a clinical sample prior to measurement by
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FIG. 1. Monoclonal hybridization assay for the detection ofviral nucleic acids. In the first step ofthe
assay, microbial RNA extracted from aclinical sampleis hybridized to a biotinylated microbe-specific DNA
probe. Following completion of the hybridization reaction, the test mixture is transferred to the wells of a
microtiter plate coated with a goat antibiotin antibody (step 2). Biotinylated DNA-RNA hybrids bound to
the solid phase are detected in a reaction with ,8-d galactosidase-labeled monoclonal antibody directed at
DNA-RNA duplexes (step 3). The assay is completed by adding a fluorescent substrate to each well and by
measuring the enzymatic reaction in microplate fluorometer (step 4).
means of nucleic acid hybridization protocols. One of the most widely used of these
techniques makes use of the enzyme DNA polymerase and flanking oligonucleotide
primers to generate amplified copies of a defined region. The steps of primer-target
annealing and enzymatic generation ofDNA can be repeated in a cyclical manner in a
format which has been termed the polymerase chain reaction [33]. While DNA
polymerase enzymes will only efficiently catalyze the amplifications of deoxyribonu-
cleotides, thepolymerase chain technique can beutilized todetectviral RNA, provided
that the RNA is converted to complementary DNA by means of reaction with the
primers and the enzyme reverse transcriptase [34]. The recent availability of a
thermostable enzyme from the organism T. aquaticus has markedly improved the
utility of this technique, since the use ofthis enzyme allows the performance ofcycles
of DNA generation, heat-induced strand separation, and re-annealing without the
need to add additional enzyme at each cycle [35].
The polymerase chain reaction offers a number of important advantages for the
detection of retroviral nucleic acids in clinical samples. In fact, polymerase chain
reaction has been applied to the detection of human immunodeficiency virus (HIV)
DNA and RNA in small numbers ofsamples. The technique has also been utilized for
the detection of HIV CMV DNA in the blood and urine of patients with CMV
infection [36,37] and HIV RNA and c-DNA in small numbers of patients with HIV
infection [34,35,38-40]. In the latter case, evidence of retroviral c-DNA has been
1.
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FIG. 2. Detection ofRNA by monoclonal hybridization assay-fluorescent substrates. Wellsofa black
microtiter plate were coated overnight at 40C with 50 MAl ofgoat antibiotin in carbonate buffer, pH 9.6, at a
concentration of 1 Mg/ml (0.25 ,ug/well). Biotinylated pSP 65 plasmid DNA (0.4Ag/ml) was hybridized to
serial dilutions ofcomplementary pSP 65 RNA transcripts for 16 hours in a hybridization buffer (2 x SSC,
20 mM HEPES, 2 mM EDTA). After the addition ofTriton-X, 50 Ml ofeach ofthe nucleic acid mixtures
were distributed on the plate coated with antibiotin Ab. After an incubation of one hour, the plates were
washed and f,-galactosidase- or alkaline phosphatase-labeled anti DNA-RNA monoclonal antibody was
added. After another washing step, thepresenceofDNA-RNA hybrids wasquantitated with theadditionof
a fluorescent substrate. Theantibody labeled with alkaline phosphatase (alk. ph.) wasdetected with 10-4 M
methylumbelliferyl phosphate in diethanolamine buffer, pH 9.6, with an incubation time of 20 minutes.
Antibody labeled withf3-d-galactosidase (,B-gal.) wasdetected with 10-4methylumbelliferyl-jt-d-galactoside
in PBS buffer, 1 mM MgCI2, 50Mg/ml BSAwith incubation timesof20and 60minutes. Thedataaremeans
ofthree values from two experiments. Detection cut-off(v): fluorescent activity ofthe probe +3 SD.
found in the lymphocytes ofhigh-risk individuals in the absenceofserological evidence
of infection. This finding suggests that the detection of HIV nucleic acids may be a
more sensitive indicator ofinfection than the development ofa measurable serological
response to HIV proteins [40,41]. The exactrelationship between thedetection ofHIV
nucleic acids by the polymerase chain reaction and the course ofHIV-related diseases
has, however, not been conclusively established.
Despite the advantages associated with these techniques, there are a number of
problems which currently impede the general application of polymerase chain-reaction
techniques for the general diagnosis of viral infections in patient-care settings [38,42].
Most important, the extreme sensitivity of polymerase chain-reaction techniques re-
quires that extreme caution be utilized in the performance ofthe reactions and that the
results of the reactions should be interpreted with caution unless extensive control
reactions are performed. Problems which can occur include contamination with small
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FIG. 3. Detection ofRNA by monoclonal hybridization assay-colorimetric substrates. The reactivity
ofthe monoclonal antibody against DNA-RNA was assessed with varying substrates and incubation times.
The assay was performed as described in Fig. 2. Antibody labeled with ,B-d-galactosidase (6-gal.) was
detected with 10-3 M nitrophenyl fl-d-galactopyranoside in 50 mM PB buffer, pH 7.2, 1.5 mM MgCl2, with
incubation times of 2 and 16 hours. Antibody labeled with alkaline phosphatase (alk. ph.) wasdetected with
10-3 M nitrophenyl phosphate in diethanolamine buffer, pH 9.6, with incubation times of 2 and 16 hours.
The data are means of three values from two experiments. Detection cut-off (v): fluorescent activity ofthe
probe +3 SD.
amounts of nucleic acid introduced during laboratory procedures and homologies with
non-viral DNA, which generate amplified sequences similar in length to the HIV target.
The problem of contamination is compounded by the extreme sensitivity of the
polymerase chain-reaction procedure, in that the presence of very small amounts of
extraneous nucleic acid can lead to the generation of a measurable signal. Contamina-
tion can occur from a number of sources, including plasmids, which are utilized as
positive controls, and amplified pieces of DNA, which are generated as part of
polymerase chain-reaction reactions in other tests.
The problem of contamination is best addressed by the use of rigorous isolation
techniques in the preparation ofthe samples and in generation ofthe amplified targets
and by the performance oflarge numbers ofcontrol reactions in which known negative
samples are processed and analyzed in a manner identical to the test sample. The
problem ofhomologies with non-viral nucleic acids which generate amplified segments
can be partially overcome by the performanceofa second hybridization reaction, using
a probe sequence homologous to a viral sequence internal to that represented by the
primer oligonucleotide. This technique, however, might not be capable ofdistinguish-
ing the probe-virus interactions from reactions between viral probes and highly
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homologous regions of the human genome. Careful studies are needed in order to
determine the extent ofthese homologies and their potential effect on the specificity of
sensitive techniques for the detection ofviral nucleic acids in human body fluids.
An additional potential limitation of polymerase chain reaction is that the target
nucleic acids must be highly conserved in order to react efficiently with the primer.
This requirement can be a particular difficulty with such viruses as HIV, since the
virus has the ability to undergo a great deal ofgenetic variation due to the low fidelity
of the HIV reverse transcriptase reaction. This problem can be partially overcome by
attempting to identify highly conserved sequences and by the use of multiple probes
[38]; however, the use of multiple probes can compound the problem of non-specific
reactions, since homology of only one of the probes with contaminating nucleic acids
will result in false-positive reactions.
In all of the above cases, the performance of control reactions would be markedly
simplified bythe inclusion ofaquantitative, non-isotopic method forthemeasurementof
the DNA amplified by the polymerase chain-reaction procedures. It is likely that the
quantitative techniques described above can be applied to the measurement of the
amplified products ofpolymerase chain reactions. The application ofthese quantitative
control reactions might markedly increase the specificity ofamplification reactions and
increase the likelihood that these procedures can be directly applied to thediagnosis and
management ofpatients with suspected viral infections. In addition, the development of
strategies for theoptimization ofassayspecificity is particularlyimportant, astheresults
of polymerase chain reactions are being utilized to support linkages between viral
infections and diseases ofidiopathic origin such as multiple sclerosis [43].
It is clear from the above discussion that nucleic acid hybridization will play an
important role in the discovery, evaluation, and diagnosis of new viral pathogens of
humans and other animals. It is still too early in the course of assay development to
state with certainty the exact roleofhybridization techniques in theclinical diagnostic
laboratory. It can be predicted with certainty, however, that advances in the basic
understanding ofviral structure, genetics, and replication willcontinue tobeapplied to
thediagnosis ofhuman infections. Furthermore, it is inevitablethatthedevelopmentof
practical techniques for the diagnosis of viral infections will lead not only to the
improved care of patients with infectious diseases, but also to the eventual control of
epidemic viral infections.
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